First-line PD-1/PD-L1 inhibitor plus chemotherapy vs chemotherapy alone for negative or < 1% PD-L1-expressing metastatic non-small-cell lung cancers.
Thierry LandreGaetan Des GuetzKader ChouahniaCherifa TalebAlain VergnenègreChristos ChouaïdPublished in: Journal of cancer research and clinical oncology (2019)
First-line anti-PD-1/PD-L1 + CT combination appears superior to CT alone for advanced, < 1% PD-L1-expressing NSCLCs for OS, PFS and ORR.